'bebtelovimab
Jump to navigation
Jump to search
Indications
* FDA revokes authorization due to circulation of non-susceptible variants[3]
* effective against Omicron variant of SARS CoV2
* bebtelovimab had been used for postexposure prophylaxis in patients at high risk for progression to severe COVID-19.[2]
* currently no FDA-approved post-exposure prophylaxis for people who may have been exposed to COVID-19[2]
More general terms
References
- ↑ Reuters staff FDA Okays New Monoclonal Antibody That's Effective Against Omicron. Medscape. Feb 11, 2022 https://www.medscape.com/viewarticle/968390
- ↑ 2.0 2.1 2.2 Bronze MS. Rapid Review Quiz: COVID-19 Updates. Medscape. Sep 28, 2022. https://reference.medscape.com/viewarticle/980879
- ↑ 3.0 3.1 Reuters. Dec 23, 2024 US FDA Revokes Authorization for Four COVID Antibody Drugs. https://www.medscape.com/s/viewarticle/us-fda-revokes-authorization-four-covid-antibody-drugs-2024a1000p08